Furthermore, targeting both the PD-1 pathway with a PD-1 inhibitor and HPK1 with an HPK1 inhibitor could broaden the immune response against cancer cells, potentially leading to better treatment outcomes because different immune checkpoint pathways may be involved in suppressing T-cell function in the tumor microenvironment. Here, MAP4K1 is linked to neoplasm.